Stockscreener 앱 받기
13.06
2.92%
0.37
시장 영업 전:
13.39
0.33
+2.53%
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC - Defense World
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26% - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6%Here's Why - MarketBeat
Geode Capital Management LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC - MarketBeat
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Where are the Opportunities in (TRDA) - Stock Traders Daily
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
(TRDA) Proactive Strategies - Stock Traders Daily
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
Charles Schwab Investment Management Inc. Has $2.97 Million Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com
Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria
Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria
Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India
Entrada Therapeutics president sells $320,619 in stock - Investing.com
Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(TRDA) Investment Analysis and Advice - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
4.81%
자본화:
|
볼륨(24시간):